SELVAS Healthcare, Inc.
KKRX:2083702,280.00
KRW
-10.00
(-0.44%)
ISIN
KR7208370007
Return %
Stock
S&P 500
1Y
-37.19
14.39
3Y
-68.64
81.42
5Y
-2.97
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Byeong-Tak Yoo
- Full Time Employees
- 139
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Daejeon South Korea
- IPO Date
- Dec 17, 2014
- Website
- selvashealthcare.com
- Similar Companies
- Business
- SELVAS Healthcare, Inc. is a South Korea-based medical technology and digital healthcare company that develops, manufactures, and distributes precision diagnostic medical devices and specialized assistive technology solutions. Founded in 1999 and headquartered in Daejeon, South Korea, with regional operations and subsidiaries including HIMS, Inc. in the United States, the company operates as a key healthcare subsidiary of SELVAS AI Inc. The company structures its core operations across two primary divisions: the Medical Device Division, focused on biometric diagnostic equipment, and the Assistive Technology Division, focused on accessibility solutions for the blind and visually impaired. The company's core product and service portfolio comprises: body composition analyzers under the ACCUNIQ brand, including multi-frequency bioelectrical impedance analysis systems such as the ACCUNIQ BC380, BC720, and BC300 series for clinical assessment of body fat, skeletal muscle, visceral fat, and body water; automated digital blood pressure monitors under the ACCUNIQ BP series, including the BP500 and BP850 models designed for clinical, institutional, and wellness facilities; cloud-connected healthcare management platforms and mobile software applications that enable remote health data monitoring, biometric trend analysis, and electronic medical record integration; refreshable braille notetakers and multimedia accessibility terminals under the BrailleSense brand, including the BrailleSense 6 and BrailleSense Polaris series equipped with customized operating systems, braille keyboards, and braille displays; electronic video magnifiers and digital reading aids under the CANDY and GoVision product lines, featuring optical character recognition, high-definition magnification, and text-to-speech capabilities; and specialized accessibility software, braille displays, and digital talking book players for educational and professional environments. SELVAS Healthcare distributes its products to hospitals, medical clinics, rehabilitation centers, government welfare agencies, educational institutions, fitness facilities, and individual consumers across domestic and international markets, exporting to over 40 countries across North America, Europe, Asia-Pacific, and the Middle East. In recent developments, the company has actively accelerated its transition into artificial intelligence-powered digital healthcare by integrating SELVAS AI proprietary speech recognition and medical AI diagnostic engines across its hardware ecosystems. Expanding its clinical diagnostics portfolio, the company entered into a strategic partnership and equity investment agreement with UltraSight, an AI cardiac ultrasound software developer, to co-develop, integrate, and commercialize AI-guided point-of-care cardiac ultrasound solutions in the South Korean and Asian markets. In addition, SELVAS Healthcare continues to advance its global footprint through international regulatory certifications for its next-generation ACCUNIQ and BrailleSense product iterations and strategic business expansions into remote patient monitoring and telemedicine infrastructure.